Prostate Cancer Clinical Trial
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Patient has NCCN low or intermediate risk prostate cancer that is biopsy proven.
Prostate volume is ≤80cc as assessed by MRI prior to radiotherapy.
AUA/IPSS score is ≤ 15.
ECOG performance status is ≤2 (or Karnofsky score is ≥60%).
Patient has no PIRADS 4 or 5 lesion on prostate MRI contacting the urethra (determined at physician discretion).
Patient has the ability to complete required patient questionnaires.
Patient age ≥ 18 years (or greater than the local age of majority).
Patient has the ability to understand and the willingness to sign a written informed consent document.
Patient has baseline grade ≥3 GI or GU toxicity
Patient has had prior overlapping pelvic radiotherapy.
Patient has had prior transurethral resection of the prostate, prostate HIFU, or cryoablation.
Patient has node positive prostate cancer.
Patient has extracapsular extension (capsular abutment is permitted).
Patient has active inflammatory bowel disease or active collagen vascular disease.
Patient cannot undergo prostate MRI.
Patient cannot undergo prostate fiducial marker placement.
Patient has ongoing receipt of cytotoxic chemotherapy (androgen deprivation therapy is allowed).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Philadelphia Pennsylvania, 19111, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.